Grade IV myelosuppression induced by gemcitabine combined with cisplatin: report of one case and review of literature

Q4 Medicine

肿瘤研究与临床 Pub Date : 2019-11-28 DOI:10.3760/CMA.J.ISSN.1006-9801.2019.11.011

H. Zemin, Liu Keting, Yu Nanbin

引用次数: 0

Abstract

目的提高对吉西他滨致骨髓抑制的识别。方法回顾性分析自贡市第三人民医院收治的1例肺鳞状细胞癌患者在化疗时发生骨髓抑制的诊治过程，并复习相关文献。结果该患者以咳嗽伴咯血入院，行支气管镜病理诊断为右肺下叶肺鳞状细胞癌伴右侧胸膜转移，患者予多西他赛、奈达铂化疗后未见明显好转，改为吉西他滨、顺铂化疗，后出现Ⅳ级骨髓抑制，给予规范化治疗后骨髓抑制得到纠正。结论对于老年晚期癌症患者，应注意吉西他滨使用剂量；出现骨髓抑制后，在后续化疗方案中应注意调整剂量或推迟使用。

查看原文本刊更多论文

吉西他滨联合顺铂诱导IV级骨髓抑制1例报告及文献复习

Objective: To improve the recognition of gemcitabine induced bone marrow suppression. Method: A retrospective analysis was conducted on the diagnosis and treatment process of bone marrow suppression during chemotherapy in a patient with lung squamous cell carcinoma admitted to the Third People's Hospital of Zigong City, and relevant literature was reviewed. The patient was admitted with cough and hemoptysis, and underwent bronchoscopy pathological diagnosis as squamous cell carcinoma of the lower lobe of the right lung with right pleural metastasis. The patient did not show significant improvement after receiving chemotherapy with docetaxel and nedaplatin, but switched to chemotherapy with gemcitabine and cisplatin. Later, grade IV bone marrow suppression occurred, and bone marrow suppression was corrected after receiving standardized treatment. Conclusion: For elderly patients with advanced cancer, attention should be paid to the dosage of gemcitabine used; After bone marrow suppression occurs, attention should be paid to adjusting the dosage or delaying use in subsequent chemotherapy plans.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

肿瘤研究与临床 Medicine-Oncology

CiteScore

0.10

自引率

0.00%

发文量

7737

期刊介绍： "Cancer Research and Clinic" is a series of magazines of the Chinese Medical Association under the supervision of the National Health Commission and sponsored by the Chinese Medical Association. It mainly reflects scientific research results and academic trends in the field of malignant tumors. The main columns include monographs, guidelines and consensus, standards and norms, treatises, short treatises, survey reports, reviews, clinical pathology (case) discussions, case reports, etc. The readers are middle- and senior-level medical staff engaged in basic research and clinical work on malignant tumors.